Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X:
“More evidence that immunotherapy works better in the morning.
In a prospective, randomized phase III trial, giving first-line chemo-immunotherapy earlier in the day (<15:00) nearly doubled PFS (11.3 vs 5.7 mo, HR 0.40) and improved OS (28.0 vs 16.8 mo; HR 0.42) in advanced NSCLC.
More effective, no added cost and easy to implement. Likely reflects circadian immune rhythms with greater CD8⁺ activation and less T-cell exhaustion.”
Title: Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial
Authors: Zhe Huang, Liang Zeng, Zhaohui Ruan, Qun Zeng, Huan Yan, Wenjuan Jiang, Yi Xiong, Chunhua Zhou, Haiyan Yang, Li Liu, Jiacheng Dai, Nachuan Zou, Shidong Xu, Ya Wang, Zhan Wang, Jun Deng, Xue Chen, Jing Wang, Hua Xiang, Xiaomei Li, Boris Duchemann, Guoqiang Chen, Yang Xia, Tony Mok, Yongchang Zhang
Read the Full Article.
Jordyn Silverstein, Medical Gynecologic Oncologist and Researcher at UCLA, shared a post by Oscar Tahuahua, adding:
“This is an alarming difference in outcome depending on time of day of immunotherapy administration
- how do we think this impacts results on previous trials?!
- They also found higher activated T cells- I would not have expected this large of a difference since these antibodies stay in the body for longer than the infusion
- this variable will be hard to control for in clinical trials moving forward but may have to be incorporated.”
